The Library
Circadian timing in cancer treatments
Tools
Tools
Tools
Lévi, Francis A., Okyar, Alper, Dulong, Sandrine, Innominato, Pasquale F. and Clairambault, Jean (2010) Circadian timing in cancer treatments. Annual Review of Pharmacology and Toxicology, Volume 50 (Number 1). pp. 377-421. doi:10.1146/annurev.pharmtox.48.113006.094626 ISSN 0362-1642.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1146/annurev.pharmtox.48.1130...
Abstract
The circadian timing system is composed of molecular clocks, which drive 24-h changes in xenobiotic metabolism and detoxification, cell cycle events, DNA repair, apoptosis, and angiogenesis. The cellular circadian clocks are coordinated by endogenous physiological rhythms, so that they tick in synchrony in the host tissues that can be damaged by anticancer agents. As a result, circadian timing can modify 2- to 10-fold the tolerability of anticancer medications in experimental models and in cancer patients. Improved efficacy is also seen when drugs are given near their respective times of best tolerability, due to (a) inherently poor circadian entrainment of tumors and (b) persistent circadian entrainment of healthy tissues. Conversely, host clocks are disrupted whenever anticancer drugs are administered at their most toxic time. On the other hand, circadian disruption accelerates experimental and clinical cancer processes. Gender, circadian physiology, clock genes, and cell cycle critically affect outcome on cancer chronotherapeutics. Mathematical and systems biology approaches currently develop and integrate theoretical, experimental, and technological tools in order to further optimize and personalize the circadian administration of cancer treatments.
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
